Analyst Scoreboard: 15 Ratings For Apellis Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Analysts have provided 15 ratings for Apellis Pharmaceuticals (NASDAQ:APLS) over the past three months, with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has decreased by 3.52% to $78.47. Analysts have adjusted their ratings and price targets based on recent developments, reflecting a cautious outlook. Apellis has shown strong revenue growth but faces challenges with profitability and debt management.
September 13, 2024 | 9:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Apellis Pharmaceuticals has received mixed analyst ratings, with a decrease in the average price target to $78.47. Despite strong revenue growth, the company faces challenges with profitability and debt management.
The mixed analyst ratings and decrease in average price target suggest a cautious outlook for Apellis Pharmaceuticals. While the company has shown strong revenue growth, its profitability and debt management challenges may weigh on investor sentiment. The short-term impact on the stock price is likely neutral as the positive revenue growth is offset by financial challenges.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100